Start Date
Not specified
Study Completion Date
September 30, 2007
Talabostat mesylate (PT-100) tablets
Rituximab
NYU Medical Center, New York
Long Island Jewish Medical Center, New Hyde Park
Queens Medical Associates, PC, Fresh Meadows
James P. Wilmot Cancer Center/University of Rochester, Rochester
Virginia Oncology Associates-Lake Wright Cancer Center, Norfolk
Wake Forest University Health Sciences, Winston-Salem
Raleigh Hematology/Oncology Clinic, Cary
Cancer Centers of the Carolinas, Seneca
Gulfcoast Oncology Associates, St. Petersburg
Ocala Oncology Center, Ocala
Indiana Oncology/Hematology Consultants, Indianapolis
Hematology/Oncology Centers of the Northern Rockies, Billings
University of Arkansas for Medical Science, Little Rock
Cancer Care Associates/Oklahoma City, Oklahoma City
Cancer Care Associates--Tulsa, Tulsa
MD Anderson Cancer Center, Houston
Nevada Cancer Institute, Las Vegas
Dana Farber Cancer Institute, Boston
Texas Cancer Center/Abilene, Abilene
Lead Sponsor
Point Therapeutics
INDUSTRY